

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/533744	First Named Inventor: Brown
371 Filing Date: May 4, 2005	Attorney Docket No.: 100886-1P US
Examiner: Emily B. Bernhardt	Group Art Unit : 1624
Customer No.: 22466	Confirmation No.: 4550
Title: 4(Phenyl-Piperazinyl-Methyl) Benzamide Derivatives and Their Use for the Treatment of Pain or Gastrointestinal Disorders	

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir,

Applicants submit herewith a list of patents and publications pursuant to the duty to disclose in accordance with 37 C.F.R. § 1.56.

In accordance with 37 C.F.R. § 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

In accordance with the U.S. Patent Office's partial waiver of the requirement under 37 C.F.R. 1.98(a)(2)(i), only copies of the foreign patent documents; English language translations of DE2900810, FR2696744, and JP7138230, which were cited in Applicants' August 12, 2005 IDS and considered by the Examiner June 23, 2007; cited International Search Report; non-patent publications; and U.S. Office Actions issued in currently and previously cited co-pending cases are enclosed.

In addition, Applicant(s) wish to call to the Examiner's attention to the following commonly-owned, co-pending patent application(s):

- 1) U.S. Application No. 10/596851, Attorney Docket No. 101260-1P US, filed on May 29, 2007;
- 2) U.S. Application No. 11/572948, Attorney Docket No. 101503-1P US, filed on January 30, 2007;

- 3) U.S. Application No. 11/743824, Attorney Docket No. 100374-2P US, filed on May 3, 2007;
- 4) U.S. Application No. 11/774935, Attorney Docket No. 100883-2P US, filed on July 9, 2007;
- 5) U.S. Application No. 11/816656, Attorney Docket No. 101692-1P US, filed August 20, 2007.

Applicants recognize that International Search Reports are not typically published on the face of an issued patent, and as a result, Examiners typically draw a line through cited International Search Report(s). Unless notified to the contrary, however, Applicants shall conclude that any lined through search report was in fact considered by the Examiner and lined through only for reasons related to the publication of the issued patent.

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed:

- (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office Action** on the merits, or before the mailing of a **first Office Action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- (2) after the period defined in (1) but before the mailing date of a **final Action** or a **Notice of Allowance** under 37 C.F.R. 1.311, and
- the requisite Statement is below, **OR**
- the Commissioner is hereby authorized to charge the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00** to deposit account No. 26-0166, referencing Attorney Docket No. 100886-1P US, or
- (3) after the mailing date of a **final Action** or **Notice of Allowance** but before the payment of the **Issue Fee**, **AND**
- the requisite Statement is below, **AND**
- the Commissioner is hereby authorized to charge the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00** to deposit account No. , referencing Attorney Docket No. , or

It is respectfully requested that each of the patents and publications listed on the attached Form SB08, and other information contained herein, be considered by the Examiner and made of record in this application.

Respectfully submitted,

/Jacqueline Cohen/

Name: Jacqueline M. Cohen
Dated: 9/27/2007
Reg. No.: 51,574
Phone No.: 302-885-4269
Global Intellectual Property, Patents,
AstraZeneca
1800 Concord Pike
Wilmington
DE-19850-5437